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Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains 
demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, 
supported by a dedicated software, including the updated recommendations. In view of this study, two surveys have been 
conducted, focusing the management of cGvHD and ancillary therapy in cGvHD, to address the current ‘real life’ situation. The two 
surveys were sent to all 57 GITMO centers, performing allografting in Italy; the response rate was 57% and 66% of the interviewed 
centers, respectively. The first survey showed a great disparity especially regarding steroid-refractory cGvHD, although 
extracorporeal photo-apheresis resulted as the most indicated treatment in this setting. Another challenging issue was the strategy 
for tapering steroid: our survey showed a great variance, and this disagreement could be a real bias in evaluating outcomes in 
prospective studies. As for the second survey, the results suggest that the ancillary treatments are not standardized in many 
centers. All responding centers reported a strong need to standardize management of cGvHD and to participate in prospective 
trials. Before starting observational and/or interventional studies, a detailed knowledge of current practice should be encouraged. 
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INTRODUCTION 
The prevalence and severity of chronic GvHD (cGvHD) have 
increased during the past 2 decades,
1,2
 likely because of (1) 
increasing use of allogeneic hematopoietic stem cell transplantation 
(HCT) in older patients, (2) the widespread use of mobilized blood 
cells instead of marrow for grafting and (3) improvements in day- 
100 mortality.
1,3,4
 Up to date, cGvHD still remains the leading cause 
of long-term nonrelapse morbidity and mortality following HCT. 
Management of cGvHD is challenging because of polymorphic 
manifestations and lack of biomarkers for the diagnosis and 
assessment of disease activity. Although the National Institute of 
Health (NIH) consortium have made a considerable effort for 
 
sharing standardized guidelines published in 2005,
5
 and more 
recently further updated,
2
 a recent meta-analysis showed little 
progress in this field.
6
 
On behalf of the Gruppo Italiano Trapianto di Midollo Osseo 
(GITMO), two questionnaires were proposed to Italian Centers 
performing allogeneic HCT, intended to address the ‘real-life’ 
management of cGvHD. Although heterogeneity of physician 
practice in allogeneic HCT has been demonstrated by many 
studies,
7–9
 these surveys were focused on the practice of the 
centers (not single physician) and potential difficulties in following 
guidelines, with the aim to better design feasible prospective 
trials. 
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Lack of comprehensive 
indications about second line 
therapy (N=4) 
Clear definition of treatment 
failure (N=3) 
Lack of evidence based decision 
(N=2) 
More details needed about 
tapering (N=2) 
First line terapy with steroid +/- 
CNI not sufficient (N=1) 
Too complicated (N=1) and no 
response (N=2) 
 
 
MATERIALS AND METHODS 
Invitations to participate in the surveys were emailed to the transplant 
program directors of all 57 centers that are part of the GITMO and that are 
performing allografting. As the aim was investigating the policies of the 
centers and not the single-physician approach, it was asked specifically to 
respond according to the common procedures of the center and not the 
individual one; the respondent was the director himself or his delegate. 
Two further reminders were sent to nonrespondents. Only one response 
per center was received, and surveys were collected using an online survey 
tool. The questions of both surveys have been preliminary discussed in a 
GITMO Meeting and reviewed by four experts in cGvHD, members of the 
GITMO GvHD Consortium and validated by the transplant team of the 
Hematology Department of Ancona. 
The first survey was sent in 2015 and included 41 multiple-choice 
questions, with a few more in-depth open-ended questions, focused on 
management of cGvHD: use of published guidelines, choice of first line of 
treatment and handling of steroid-refractory cGvHD (see Supplementary 
Files 1a and b). 
A second survey was sent in 2016 to investigate the use and diffusion of 
ancillary therapy and supportive care in patients affected by cGvHD: it 
consisted of 30 multiple-choice questions investigating business organiza- 
tion, medical needs, nursing, counseling and consultative medicine (see 
Supplementary Files 2a and b). 
As applicable, participant and transplant center demographics and 
responses are summarized using descriptive statistics. 
 
RESULTS 
General issues 
In the 6-month time frame, the survey on cGvHD management 
was accomplished by 32 respondents (28 adult transplant centers 
and 4 pediatric centers) for a response rate of 56%, similar to other 
reports.
7–9
 In 2015, the median number of allogeneic transplants 
in the responding centers was 22 (range 2–78); 17/32 respondents 
belonged to academic hospital and 15 to community hospital. 
Answers from pediatric and adult centers did not differ, but only 
four pediatric centers completed the survey. 
Twenty-nine centers referred to published guidelines for cGvHD 
management (Table 1). For diagnosis, most of them (N = 14) 
referred to guidelines proposed by the NIH or similar,
2,5,10,11
 
whereas the most cited guidelines for treatment were those of 
British and EBMT (European Society for Blood and Marrow 
Transplantation),
12–14
 and those proposed by Wolff et al.
15
 
(Table 1). The NIH, British and European guidelines differ only 
for small details, but only 13/33 centers found them fully 
satisfactory. The main reasons for lack of satisfaction concerned 
the second-line approach (when to start treatment, treatment 
choice and/or absence of clear evidence in this setting) (Figure 1). 
At the time of survey, only three centers had a cGvHD trial open, 
all for steroid-refractory cGvHD. 
 
First-line treatment 
The criterion to start systemic treatment was the occurrence of 
moderate or severe cGvHD defined as per NIH indications
5,16
 in 25 
Figure 1. Are you satisfied by the current guidelines about  
chronic GvHD? 
 
centers, and as per Shulman et al.
17
 in 1 center, whereas 4 centers 
also considered the presentation with bad prognostic features, 
regardless the grading, and 2 centers treated all patients 
diagnosed with cGvHD. 
All centers indicated prednisone as first-line treatment that was 
started at the dose of 1 mg/kg in 27/32 centers, at 0.5 mg/kg in 4 
centers and at 2 mg/kg in 1 center. Four centers used prednisone 
as single agent, whereas 28 preferred an association with other 
treatments: extracorporeal photo-apheresis (ECP, N = 25), calci- 
neurine inhibitors (N = 17) and mycophenolate mofetil (MMF, 
N = 11), sirolimus (N = 2), imatinib (N = 2), pentostatin (N = 1) and 
rituximab (N = 1). 
A broad inter-center variety has been reported regarding the 
duration of treatment, as well as the indication to and the choice 
of steroid-sparing agents. All but 6 centers used the updated NIH 
criteria to define response. Objective measurements (that is, 
pulmonary function and lab tests), patient reports and ability to 
treatment discontinuation were scored as very relevant for 
response judgment, whereas physician opinion was scored as 
medium. To evaluate response to treatment, 12 centers con- 
sidered a fixed timepoint (such as 3 months), whereas 18 believed 
that response should be assessed at multiple timepoints to 
determine whether the benefit is sustained (2 not answered). In 
case of complete response, 30/32 centers tapered steroid slowly, 
but there was no uniformity on the definition of slow taper 
(Figure 2). In case of partial response, 18/33 centers tapered 
steroid as slowly as in complete response, 11/33 tapered steroid 
more rapidly and added another agent (3 no response). 
 
Refractory cGvHD 
Treatment failure, steroid refractoriness, dependency or intoler- 
ance were the main reasons for second-line therapy. Treatment 
failure was defined as follows: (1) progression or lack of response; 
and (2) clinically relevant flares of cGvHD within the first 3 months: 
2 flares in 3 months according to 15 centers, 1 flare in 7 centers, 3 
flares in 7 centers and 2 centers waited for more than 3 flares 
(1 did not answer). Twenty-two centers adopted the definition of 
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steroid dependency proposed by NIH: 40.25 mg/kg/day needed 
to prevent recurrence or progression of manifestations as 
demonstrated by unsuccessful attempts to taper the dose to 
lower levels on at least 2 challenges, separated by at least 8 
weeks.
18
 Six centers did not agree to wait 8 weeks and used a 3–5- 
week time frame instead, 3 centers disagreed with NIH criteria
18
 
without specifying their policy and 2 centers did not answer. 
Uncontrolled diabetes, hypertension, osteoporosis and psychosis 
were scored by at least 15 centers as main reasons for steroid 
intolerance. 
Of the 32 centers, 26 usually considered second-line therapy 
between 4 and 8 weeks after initial approach. After the initial 
failure, 24 centers would use a different drug, whereas 7 would 
not (2 not answered). Sixteen centers had a policy for the choice 
of second-line treatment, and the choice was customized 
according to organ involvement and patient conditions in 24/32 
centers (Table 2). Seven centers declared a policy for third line of 
treatment (Table 2). Overall, calcineurine inhibitors, ECP and MMF 
were the most used treatments for refractory cGvHD: calcineurine 
inhibitors regardless of the involved organ, ECP and sirolimus for 
skin, lung and gastrointestinal involvement, imatinib for skin and 
lung, infliximab and MMF for liver and gastrointestinal and 
rituximab for skin. 
ECP was available in 25/32 centers (78%): ECP is delivered via 
‘closed’ in 7 and via ‘open’ system in 16 centers. Patients were 
treated with ECP on 2 consecutive days at weekly intervals for the 
first month, then waned according to different schedules in 10 of 
the 25 centers; the ECP program was not declared in 11 centers, 
whereas it was as follows in the others: 2 consecutive days every 
other week (N = 2), 2 consecutive days weekly for 2–3 months 
(N = 1) and once weekly (N = 1). As shown in Table 2, ECP is often 
used for refractory cGvHD with cutaneous and mucosal 
involvement. 
At the time of survey, 14 and 5 centers had 10–20 and 420 
patients on active treatment for cGvHD, respectively. Figure 3 
shows patient distribution according to centers and ongoing 
treatments. 
Ancillary therapies and supportive care interventions 
The survey on ancillary therapy was completed by 38 centers (32 
adults and 6 pediatric), for a response rate of 67%, without 
differences raised from pediatrician centers. In 2015, the median 
number of transplants in the responding centers was 26. 
The first set of questions focused on business organization 
(guidelines, presence of medical and nurses standard operating 
procedures (SOPs)). All centers declared to be compliant with the 
first consensus including the NIH recommendations,
19
 and 31 out 
38 had active projects or dedicated personnel to at least one 
aspect of ancillary therapy in their transplant programs. However, 
comprehensive medical procedures focused on topical therapies 
and drug-free collateral interventions were declared by 7 centers 
only. Fourteen centers did not mention ancillary therapies in their 
SOPs. Only 10 out 38 centers had specific SOPs for nursing care, 
whereas 13/38 centers included nurse tasks into some 
medical SOPs. 
Then, the survey inquired about the presence of specific SOPs 
for each organ potentially target of ancillary therapies. As 
expected, the most covered issue was prevention and manage- 
ment of infectious disease (31/38 centers had dedicated SOPs), 
followed by oral (25 centers), lung (21), gynecologic (20) and eye 
care (18); neurocognitive functioning, depression and anxiety 
together were mentioned by all pediatric centers and only 7 adult 
ones. The results indicated that most of the centers have SOPs 
including some aspects of ancillary therapies, but very few of 
them accomplished all organs possibly involved. Similarly, many 
centers referred to specialists for multidisciplinary approach of 
cGvHD complications; however, 23/38 complained of the lack of 
consultant experts on organ-specific manifestation of cGVHD. 
Consequently, very few consultants felt competent enough to 
build a network of GITMO panel of experts. 
Further questions investigated the degree of counseling about 
cGvHD late complications and quality of life post HCT. The 
majority (31/38) of centers addressed these topics before HCT, 
although only 20 of them believed to be exhaustive. 
 
Future developments 
All responding centers reported a strong need for and willingness 
to standardize first-line approach to cGvHD as, despite the 
accordance in the use of prednisone, the practical aspects 
remained uncertain: dose, management of toxicity, duration, 
taper and definition of common response criteria. Furthermore, 
there was a strong interest in prospective trials for steroid- 
refractory cGvHD. Only 2 centers have already had a protocol 
open for refractory GvHD. 
Furthermore, all centers agreed to an incoming GITMO 
 
 
 
 
 
 
 
 
Despite the high level of knowledge of the published guidelines, 
 
 
 
 
 
patients with NIH-defined cGvHD, the median duration of 
systemic treatment from time of original onset was 28.7 months 
(range, 0.9–115 months),
21
 meaning that the impact of this rare 
Table 2. Centers’ choice for refractory cGvHD according to organ 
involvement 
Second-line treatments 
(10 centers) 
Third-line treatments 
(3 centers) 
Abbreviations: cGvHD = chronic GvHD; CNI = calcineurin inhibitor; ECP = 
extracorporeal photo-apheresis; GI = gastrointestinal; MMF = mycopheno- 
late mofetil; PUVA = photochemotherapy. 
 Skin GI Liver Lung Skin GI Liver Lung clarifying note on allogeneic HCT complications (GvHD, late 
mucosa    mucosa    complications and quality of life), properly revised, that may be 
CNI 2 2 3 2 0 0 0 0 used by all Italian transplant centers. With this platform, the 
PUVA 1 0 0 0 0 0 0 0 GITMO GvHD Consortium designed a prospective censoring of 
ECP 7 4 3 2 1 1 2 1 cGvHD onset supported by a specific software based on the NIH 
Imatinib 3 0 0 7 2 0 0 1 diagnostic and response criteria. 
Rituximab 3 0 0 0 2 0 0 0  
Sirolimus 1 1 0 2 0 1 0 1  
Methotrexate 
High-dose 
steroids 
1 
0 
0 
0 
1 
0 
0 
1 
2 
0 
0 
0 
0 
0 
1 
0 
DISCUSSION 
MMF 0 2 4 0 0 0 2 0 this survey showed a great disparity in the management of 
Anti-TNFα 0 3 1 0 0 1 0 0 cGvHD, especially for steroid-refractory disease. Similarly, an 
Azathioprine 0 1 1 0 0 0 1 0 international survey to assess the uptake of NIH recommendations 
Pentostatin 
Montelukast 
0 
0 
2 
0 
0 
0 
0 
1 
0 
0 
1 
0 
0 
0 
0 
0 
conducted by EBMT–National Cancer Institute Chronic GVHD Task 
Force identified the therapeutic management of steroid-refractory 
Azitromycin 0 0 0 1 0 0 0 0 cGvHD as the highest priority for research.
20
 In a group of 235 
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Figure 3. Patients on ongoing treatment for chronic GvHD. (a) Number of centers divided by the number of patients on current treatment. 
(b) Type of ongoing treatments. CNI, calcineurin inhibitor; MTX, methotrexate; TKI, tyrosine kinase inhibitor. 
 
disease is still high, and further efforts should be done to improve 
treatment and quality of life. 
This survey has been planned not only with the aim of 
collecting reliable information about the real-life practice in the 
Italian centers, but also because a new prospective observational 
study in newly diagnosed cGvHD was planned in the Italian 
GITMO centers. This noninterventional study will focus both on 
response evaluation (according to the updated NIH criteria) and 
long-term outcome with the support of a dedicated software that 
utilizes a complex algorithm to calculate both the single organ 
and the global response. In order to start this trial in all centers, 
based on a homogeneous platform, there was a general 
agreement about the need to define some basic standards about 
the major policies for the cGvHD management in the different 
Italian centers. These two surveys have been planned in order to 
have a common background and to speak the same language in 
this field; this aspect should be considered a true medical need, 
not only for some apparently shared definition of standard first- 
line treatment (including duration an tapering schedules), but also 
for the standardization of the ancillary treatments. 
As expected, despite some inter-center disagreements, systemic 
corticosteroids were reported to be the first-line treatment for 
cGvHD in all GITMO centers; however, most of the centers 
associated steroids with ECP upfront, with the aim of increasing 
response rate and sparing steroids. The use of prednisone as first- 
line therapy is indeed widely supported by literature,
10,12,14,22
 but 
randomized trials did not show any benefit from adding other 
drugs such as MMF,
23
 azathioprine,
24
 thalidomide
25
 or 
hydroxychloroquine
26
 to initial treatment of cGvHD. Furthermore, 
a trial comparing cyclosporine plus prednisone with prednisone 
alone showed no statistically significant differences in survival or 
the duration of treatment.
27
 As for other alternative treatments 
(such as ECP) to be associated upfront with steroids, there are no 
clear evidences supporting its association, although this approach 
is theoretically attractive, given its tolerability and efficacy as 
second-line treatment. 
Regarding first-line treatment, another challenging issue is the 
strategy for tapering steroid: our survey showed a great variance, 
mainly because of concern about side effects, although a rapid 
taper may cause cGvHD flares. A prototypic taper schedule 
proposed by the Seattle group
10
 is designed to approximate a 20 
to 30% dose reduction every 2 weeks, with smaller absolute 
decrements toward the end of the taper schedule, with 
adjustment according to disease response and toxicities. 
General indications for secondary treatment include worsening 
manifestations in a previously affected organ, development of 
manifestations in a previously unaffected organ, absence of 
improvement after 1 month of treatment or inability to decrease 
the dose of prednisone below 1.0 mg/kg per day within 2 
months.
10,15,18
 In the GITMO survey, the general concepts 
appeared preserved, although there is some variability in the 
details mainly because of concerns about drug side effects as well 
as disease severity. 
No consensus has been reached regarding the optimal choice 
of agents for secondary treatment of cGvHD. Treatment choices 
were based on physician experience, ease of use, need for 
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monitoring, kind of potential toxicity and risk of exacerbation of 
preexisting comorbidity.
10,15
 Reports from the retrospective and 
prospective studies on this field indicated high response rates, but 
results remain difficult to interpret because of deficiencies in study 
design.
6,10
 As consequence, in a recent consensus conference, 
steroids only achieved a strength of evidence level BIII-I, whereas 
all other options were graded less.
15
 According to the cGvHD 
survey, ECP and MMF were the most widely used treatments, 
other than rechallenge with steroids and calcineurine inhibitors, 
and this is in line with most of the published indications.
15
 
ECP was available in 25/33 centers and widely used, although 
with different schedules and not on many patients (Figure 3b). 
Recent recommendations from the Italian Society of Hemapher- 
esis and Cell Manipulation and the GITMO included ECP in both 
adults and pediatric patients with cGvHD, either steroid resistant 
or steroid dependent.
28
 ECP increases the costs for the manage- 
ment of GvHD, but the clinical improvement obtained through 
ECP makes the incremental costs economically ‘acceptable’.
28
 
Steroid-refractory cGvHD is an orphan disease without 
approved therapy, has low appeal for the companies, and this 
disease is very difficult to manage, with multiorgan involvement 
and unpredictable trajectory and response. The inter-center 
discrepancies in its management reflected more the complexity 
and polymorphism of the disease than the lack of clear and 
trusted guidelines. In 2011, Wolff et al.
15
 published a consensus on 
the current evidence of treatment options for steroid-refractory 
cGvHD: ECP, thalidomide and methotrexate showed higher 
efficacy on mucocutaneus manifestations, rituximab on sclero- 
derma and autoantibody-mediated cytopenia, etanercept and 
infliximab in gastrointestinal GvHD and imatinib, on the basis of its 
antifibrotic activity, on sclerodermic and mild lung manifestations. 
Although different treatment options are available, the sparse 
evidence for most treatment entities indicates the urgent need for 
specific trials. 
The delayed immune reconstitution, caused by disease and 
treatment targeting the immune system, the refractory nature of 
cGvHD-related fibrosis and the limited success of systemic 
immunomodulatory treatments lead to significant persistence of 
morbidity for prolonged periods of time. Thus, ancillary therapies 
and supportive care became central components in the long-term 
management of cGvHD after HCT for most of the centers. For a 
comprehensive patient care, multidisciplinary approach involving 
different specialists is mandatory; however, lack of dedicated 
consultants and personnel emerged as the main pitfall in the 
survey, and more efforts are required in this field. 
A particular scenario of jammed drug development happened; 
indeed, the overestimation of the response rate generated a 
plethora of promising drugs/interventions, making it difficult to 
select a shared investigational drug to compare with an undefined 
standard treatment. Today, after a long period of stagnation, new 
approaches for cGvHD treatment have been proposed thanks to 
the recent advances of our understanding of cGvHD 
pathophysiology
29
 these new opportunities should start a new 
era of randomized clinical trials in this field after decades of small- 
size phase 2 trials or retrospective studies. However, a reliable tool 
for response evaluation is mandatory in order to avoid an 
overestimation of the response rate that is a common finding in 
most old-generation studies where the NIH response criteria have 
not been extensively used. 
Overall, all involved GITMO centers professed a great interest 
and need for prospective trials investigating this setting. In this 
view and given the discrepancies enlightened by the surveys, a 
prospective observational study conducted by the GITMO is 
ongoing. This study will employ a software for cGvHD manage- 
ment that allows the automatic calculation of the global severity 
score of cGvHD, according to the recent NIH consensus and the 
standardized evaluation of the response in the different organs. 
Furthermore, these surveys raised the need of common GITMO 
SOPs that should include sharing consultants and specific centers' 
skills. These facilities should constitute a solid foundation for 
subsequent reliable interventional prospective studies. 
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